3.40
前日終値:
$3.08
開ける:
$3.21
24時間の取引高:
651.24K
Relative Volume:
0.83
時価総額:
$143.54M
収益:
$20.72M
当期純損益:
$-100.84M
株価収益率:
-1.2782
EPS:
-2.66
ネットキャッシュフロー:
$-78.56M
1週間 パフォーマンス:
+9.68%
1か月 パフォーマンス:
-13.27%
6か月 パフォーマンス:
-58.84%
1年 パフォーマンス:
-87.12%
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
名前
4 D Molecular Therapeutics Inc
セクター
電話
(510) 505-2680
住所
5858 HORTON STREET #455, EMERYVILLE
FDMT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
FDMT
4 D Molecular Therapeutics Inc
|
3.40 | 143.54M | 20.72M | -100.84M | -78.56M | -2.66 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-01-13 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2024-11-21 | 開始されました | Morgan Stanley | Underweight |
2024-09-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2024-04-15 | 開始されました | Barclays | Overweight |
2024-02-07 | 再開されました | Goldman | Buy |
2023-10-26 | 開始されました | RBC Capital Mkts | Outperform |
2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
2023-10-18 | アップグレード | Leerink Partners | Market Perform → Outperform |
2023-07-05 | 開始されました | Chardan Capital Markets | Buy |
2023-01-30 | 開始されました | BMO Capital Markets | Outperform |
2022-11-18 | 開始されました | H.C. Wainwright | Buy |
2022-11-15 | アップグレード | Goldman | Neutral → Buy |
2022-08-12 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2022-06-22 | 開始されました | Jefferies | Buy |
2022-01-04 | 開始されました | SVB Leerink | Outperform |
2021-01-05 | 開始されました | BofA Securities | Buy |
2021-01-05 | 開始されました | Evercore ISI | Outperform |
2021-01-05 | 開始されました | Goldman | Neutral |
すべてを表示
4 D Molecular Therapeutics Inc (FDMT) 最新ニュース
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & Gilead Sciences (NASDAQ:GILD) - Defense World
JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What is Leerink Partnrs’ Estimate for FDMT FY2026 Earnings? - Defense World
Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
Retinitis Pigmentosa Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics - Barchart.com
American Century Companies Inc. Acquires 4,429 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Wellington Management Group LLP Purchases 11,089 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
8,600 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Acquired by KLP Kapitalforvaltning AS - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4D Molecular Therapeutics, Inc. (FDMT) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - ACCESS Newswire
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Raymond James Financial Inc. Takes Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India
4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register
Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $30.63 Average PT from Analysts - The AM Reporter
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World
M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World
4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com
4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire
4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan
Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World
FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World
Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex
4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance
Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World
Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World
4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga
4 D Molecular Therapeutics Inc (FDMT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):